3 Big Pharma Dividend Stocks Built for Retirement Income

Published November 19, 2026, 12:47pm ET · 5 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

2 a pharmacist in a white coat one checks stock on shelves while holding a tablet and stylus
© Hiraman / E+ via Getty Images

A retirement portfolio needs income that holds up through patent cliffs, and the world’s largest drugmakers have spent decades replacing old blockbusters with new ones while the dividend checks keep coming. Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction), Novartis (NYSE:NVS) and Sanofi (NASDAQ:SNY) all pay their dividends out of global businesses in cancer, cardiology, immunology and vaccines. On its latest earnings call, Sanofi’s finance chief pointed to 31 consecutive years of dividend increases[1]. Below, each company gets a look at how well its dividend is covered, what pays for it and the one risk worth watching.

Bristol Myers Squibb: Quarterly Checks Backed by Eight Billion-Dollar Drugs

Bristol Myers pays $0.63 per share every quarter, or $2.52 a year. At the current price of $59.13, that’s a 4.26% yield. The stock is the only quarterly payer in this group and a high-yield name trading at about 9 times forward earnings.

Dividend Safety

The payout is well covered. The dividend takes up 55.9% of trailing GAAP earnings per share of $4.51 and 39.7% of the low end of management’s non-GAAP EPS guidance of $6.35 to $6.55[2]. Each quarterly payment costs roughly $1.29 billion. Operating cash flow last quarter was $4.2 billion[2]. Total debt is about $42.9 billion[2], partly offset by roughly $13 billion[3] in cash, cash equivalents, and marketable securities. The track record is solid: the quarterly rate has gone up every year since 2010, when it was $0.32. The most recent raise was small, taking it from $0.62 to $0.63.

Bull Case

Newer drugs are making up for the older ones. Growth Portfolio revenue rose 12% to $7.66 billion[2] last quarter, and eight[3] of those medicines now bring in more than $1 billion a year at their current sales rate. Breyanzi grew 48%[3], Camzyos rose 42%, and Symvexis just won FDA accelerated approval in multiple myeloma. Chief Financial Officer David Elkins said the company is “continuing to return cash to our shareholders through our commitment to the dividend.”[3]

Risk to Watch

Eliquis brought in $4.69 billion[2] last quarter, which makes it the biggest single threat to cash flow. It loses exclusivity in Europe this quarter[3]; management expects a $1.5 billion to $2 billion Eliquis revenue drop next year, and the drug’s Medicare negotiated price is now in effect under the federal drug price negotiation program. Management already cut its non-GAAP EPS guidance from $6.75 to $7.00.

BMY price target

Novartis: Nearly 30 Years of Franc-Based Dividend Growth

Novartis made a single annual payment of about $4.77 per ADS. At $153.12, that is a 3.12% yield, the lowest of the three, and the stock trades at about 16 times forward earnings. Novartis is a Swiss company that pays once a year, so the dollar amount U.S. holders receive moves with the franc and is reduced by Swiss withholding tax. Of the company’s $9.068 billion[4] gross dividend, $2.9 billion went to Swiss withholding tax.

Dividend Safety

Free cash flow easily covers the dividend. Novartis generated $14 billion[5] of free cash flow in the first nine months of the year, well above the annual gross dividend. On trailing IFRS earnings of $5.24 per share, the payout comes to 91.1%. That figure is inflated by a $1.94 billion[6] del-desiran impairment and a $600 million contract provision. Core EPS was $2.46[6] for the quarter. Net debt is $37.4 billion[6] with debt-to-equity of 1.23:1. Chief Executive Vas Narasimhan said, “We grow the dividend in Swiss francs every year, as we have now done for almost 30 years.”[5] In dollars, the most recent payment rose from $3.99399 to $4.772961. Currency can still eat away the dollar check, though: the payment slid from $3.3783783 to $3.3574492 in one year.

Bull Case

The drugs Novartis is counting on for growth are delivering. Kisqali sales rose 37% to $1.82 billion[6], Scemblix grew 66%, and Leqvio rose 64%, driving core operating margin to 41.6%. The company raised its core operating income guidance, still has $4.9 billion[5] left to buy back under its up-to-$10 billion program, and raised its blockbuster drug forecasts today.

Risk to Watch

Generic competition is hitting Entresto, whose sales fell 38% to $1.17 billion[6], and Xolair biosimilars are expected to pressure margins over the next couple of years. Novartis also set a lower annual sales growth target through 2031 today, so investors are likely to watch closely how quickly new products can replace older revenue.

NVS price target

Sanofi: Highest Yield and a 31-Year Raise Streak

Sanofi paid about $2.42 per ADS in its latest annual payment. At $46.06, that is a 5.26% yield, the highest in this group and comfortably high-yield. The stock trades at about 9 times forward earnings. Sanofi is French and pays once a year in euros, so U.S. holders’ dollar payment moves with exchange rates and may be reduced by French withholding tax. Even with euro raises every year, the dollar payment fell from $1.909748 to $1.609295 over one period.

Dividend Safety

Measured by cash, coverage is strong. Year-to-date free cash flow reached €6,993 million[7], already more than the €4.923 billion[8] annual dividend. On trailing IFRS earnings of $2.01 per share, the payout looks like 120.5%. Business EPS, the figure management uses to guide, rose 17.1% to €3.97[8] in the first half. Net debt stood at €15.513 billion, and gearing was 22.3%. CFO François Roger described “a conservative financial policy”[1] built around a strong investment-grade rating and “31 consecutive years of dividend increases in absolute value in euros.” In dollars, the latest payment rose from $2.212154 to $2.422477.

Bull Case

Dupixent is still growing fast. Sales rose 34.8% to $6.36 billion[7] last quarter, with growth in all nine[1] approved uses, and management backed its target of EUR 25 billion in Dupixent revenue by 2030. Sanofi also raised its full-year guidance to low-teens[7] sales growth and mid-teens business EPS growth.

Risk to Watch

A large share of Sanofi’s earnings depends on Dupixent, which faces loss of exclusivity over the next decade. Chief Executive Belén Garijo said, “Our current focus is going to be really preserving earnings,”[1] so the dividend’s long-term growth depends on new drugs and dealmaking filling that gap.

SNY price target

How the Three Pharma Payers Compare for Retirement Income

All three fund their dividends from diversified global drug portfolios, and free cash flow covers each payout even where accounting charges make earnings look thin. Bristol Myers offers a quarterly check and a 4.26% yield at a low earnings multiple. Sanofi offers the most income and a 31-year euro raise run. Novartis has nearly 30 years of steady growth in its home currency. The two foreign names make one payment a year, with dollar amounts that move with exchange rates.

Contact [email protected] for any questions or corrections.

Chris Lange

Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.

His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.

When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.

All articles →

Sources

  1. Sanofi Q3 2026 earnings callSanofi
  2. Bristol-Myers Squibb Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission
  3. Bristol-Myers Squibb Company Q3 2026 earnings callBristol-Myers Squibb Company
  4. Novartis Form 6-K (Q2 FY2026)U.S. Securities and Exchange Commission
  5. Novartis AG Q3 2026 earnings callNovartis AG
  6. Novartis Form 6-K (Q3 FY2026)U.S. Securities and Exchange Commission
  7. Sanofi Form 6-K (Q3 FY2026)U.S. Securities and Exchange Commission
  8. Sanofi Form 6-K (Q2 FY2026)U.S. Securities and Exchange Commission